Sabtu, 21 Mei 2016

Betaville

Betaville

Nutmegged on SOBI

Posted: 20 May 2016 11:44 AM PDT

Hacks over at FT Alphaville have pulled the trigger on the Swedish Orphan Biovitrum takeover tale. Here is a link to the piece:

http://ftalphaville.ft.com/2016/05/20/2162592/friday-raw-are-bidders-circling-sobi-again/

Naturally, I'm rather gutted because I have spent of lot effort trying to stand up a similar story all week although my version of events is slightly different.

So, now the cat is out of the bag I might as well provide the gory detail I have come across.

According to sources, rare disease maker Sobi has been working with advisers from BNP Paribas and a US-based specialist boutique called MTS Partners after receiving expressions of interest from both Biogen and Actelion around the 190 SEK level.

Biogen is said to be working with JP Morgan and Lazard whilst Actelion has lined a multi-billion dollar debt financing package from HSBC to pursue Sobi.

The situation is fluid, or potentially stuck in the mud, because Investor, the largest shareholder in Sobi, is said to be holding out for a higher price from Biogen and Actelion or participating in Biogen's spin off of its haemophilia division. Investor is the billionaire Wallenberg family's investment vehicle and owns around 40pc of Sobi.  

As for Pfizer, I don't know too much about its interest but it would seem obvious that it may also be keen on buying Sobi as it made an approach last year.

A spokesperson for Sobi declined to comment.

To be clear, all of the above information is RARE of the RAREST kind. If you are unfamiliar with what RARE is, here is the definition:

Market gossip that hasn't been tested through formal journalistic channels (public relations executives, bankers etc). The rumour might be total codswallop but then again there may be something in it, so it's worth airing on Betaville.
Diposting oleh di

Tidak ada komentar:

Posting Komentar

Langganan: Posting Komentar (Atom)